Added to YB: 2024-07-15
Pitch date: 2024-07-15
VRCI.L [bullish]
Verici Dx plc
-87.59%
current return
Author Info
No bio for this author
Company Info
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Market Cap
GBP 20.5M
Pitch Price
GBP 0.07
Price Target
0.20 (+2253%)
Dividend
N/A
EV/EBITDA
-2.42
P/E
-1.65
EV/Sales
18.14
Sector
Biotechnology
Category
growth
Verici Dx - $VRCI.L
VRCI.L: Kidney transplant diagnostics firm. H1'24 rev $3.3m vs $1.0m FY23. $2.8m/$5.0m received from TMO deal. 20p PT. Est. 90% margins, $9m fixed costs. $7.5m/$13.0m rev 2024/25, $1.3m EBITDA 2025. $7.0m cash. Protega study H1'25. Tutivia sold in US. Seeking Medicare cover ($2,650/test). RNA signature tech: 79% PPV for Tutivia.
Read full article (2 min)